Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

PURPOSE: The originator abiraterone acetate (OAA) formulation is used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the bioavailability and bioequivalence of a novel formulation, abiraterone acetate fine particle (AAFP), versus OAA on a steady-sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussaini, Azra, Olszanski, Anthony J., Stein, Cy A., Bosch, Bill, Nemeth, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573754/
https://www.ncbi.nlm.nih.gov/pubmed/28695267
http://dx.doi.org/10.1007/s00280-017-3360-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573754/
https://www.ncbi.nlm.nih.gov/pubmed/28695267
http://dx.doi.org/10.1007/s00280-017-3360-3

Ejemplares similares